Aspen Neuroscience files for an IPO

Aspen Neuroscience develops autologous induced pluripotent stem cell therapies for neurodegenerative diseases. Its lead candidate, sasineprocel, is an investigational single-dose cell therapy being evaluated for Parkinson’s disease.